Table 2 Predictors of progression-free survival and overall survival after matching

From: Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

 

Univariable analysis

Multivariable analysis

 

HR

95% CI

P-value

HR

95% CI

P-value

PFS analyses

ECOG PS (1 vs. 0)

1.10

0.85–1.41

0.466

   

Etiology (HBV vs. others)

0.92

0.72–1.18

0.532

   

Cirrhosis (present vs. absent)

1.05

0.81–1.36

0.706

   

Child-Pugh class (B vs. A)

1.27

0.94–1.72

0.123

   

BCLC stage (C vs. B)

1.75

1.37–2.23

<0.001

1.50

0.96–2.34

0.073

Up-to-seven criteria (>7 vs. ≤7)

1.42

1.09–1.86

0.010

1.27

0.95–1.69

0.103

Macroscopic portal vein invasion (present vs. absent)

1.47

1.17–1.85

0.001

1.01

0.71–1.45

0.939

Extrahepatic spread (present vs. absent)

1.46

1.15–1.85

0.002

1.16

0.84–1.61

0.360

TACE type (DEB-TACE vs. cTACE)

1.06

0.82–1.36

0.677

   

HCC-related treatment history (present vs. absent)

0.63

0.49–0.81

<0.001

0.76

0.48–1.19

0.224

Previous TACE history (present vs. absent)

0.66

0.50–0.87

0.004

0.95

0.59–1.54

0.837

Treatment (combination therapy vs. monotherapy)

0.76

0.60–0.95

0.016

0.70

0.56–0.88

0.002

OS analyses

ECOG PS (1 vs. 0)

1.12

0.83–1.52

0.461

   

Etiology (HBV vs. others)

0.87

0.64–1.17

0.345

   

Cirrhosis (present vs. absent)

1.05

0.76–1.44

0.765

   

Child-Pugh class (B vs. A)

1.56

1.10–2.21

0.013

1.21

0.84–1.74

0.307

BCLC stage (C vs. B)

1.84

1.36–2.49

<0.001

1.14

0.66–1.98

0.631

Up-to-seven criteria (>7 vs. ≤7)

1.81

1.27–2.59

0.001

1.49

1.03–2.17

0.034

Macroscopic portal vein invasion (present vs. absent)

1.75

1.33–2.31

<0.001

1.32

0.84–2.05

0.225

Extrahepatic spread (present vs. absent)

1.49

1.12–1.98

0.007

1.29

0.88–1.89

0.200

TACE type (DEB-TACE vs. cTACE)

1.08

0.79–1.49

0.621

   

HCC-related treatment history (present vs. absent)

0.46

0.34–0.63

<0.001

0.54

0.30–0.96

0.037

Previous TACE history (present vs. absent)

0.54

0.38–0.77

0.001

1.05

0.56–1.96

0.881

Treatment (combination therapy vs. monotherapy)

0.75

0.57–0.98

0.037

0.63

0.47–0.83

0.001

  1. The multivariable analysis includes the variables with P-value ≤0.1 from the univariable analysis
  2. HR hazard ratio, CI confidence intervals, ECOG PS Eastern Cooperative Oncology Group performance status, HBV hepatitis B virus, BCLC Barcelona Clinic Liver Cancer, TACE transarterial chemoembolization, cTACE conventional TACE, DEB-TACE drug-eluting beads TACE, HCC hepatocellular carcinoma
Back to article page